<p>根据彭博社报道，Cantor Fitzgerald 在周三发布的一份报告中重申了对 89bio（纳斯达克股票代码：ETNB）的&#34;超重&#34;评级。他们目前将该股票的目标价定为 29.00 美元。Cantor Fitzgerald 的目标价表明，与公司前一交易日收盘价相比，潜在上涨幅度为 194.72%。</p>
<p>一些其他股票研究分析师最近也对 ETNB 发表了评论。加拿大皇家银行将 89bio 的目标价从 15.00 美元降至 14.00 美元，并在 3 月 1 日的报告中给予该股票&#34;行业表现&#34;评级。美国银行在 4 月 22 日的报告中重申了&#34;买入&#34;评级，并将 89bio 的目标价设定为 30.00 美元。Oppenheimer 在 3 月 5 日的报告中重申了对 89bio 的&#34;市场表现&#34;评级。HC Wainwright 在周二的报告中重申了对 89bio 的&#34;买入&#34;评级，并将目标价设定为 29.00 美元。最后，Evercore ISI 在 5 月 15 日的报告中将 89bio 的目标价从 37.00 美元降至 33.00 美元，并给予该股票&#34;跑赢市场&#34;评级。两位投资分析师对该股票进行了持有评级，而五位则给予了买入评级。根据 MarketBeat.com 的数据，公司的共识评级为&#34;中等买入&#34;，平均目标价为 28.14 美元。</p>
<p><strong>查看我们对 89bio 的最新分析</strong></p>
<h2>89bio 股票表现</h2>
<p>纳斯达克 ETNB 周三上涨 1.16 美元，报 9.84 美元。公司股票交易量为 355,360 股，相比平均交易量 1,108,966 股有所减少。公司市值为 9.6806 亿美元，市盈率为-4.91，β系数为 1.11。公司流动比率为 15.03，速动比率为 15.03，负债权益比为 0.05。公司的 50 天移动平均价格为 8.98 美元，200 天移动平均价格为 10.13 美元。89bio 的 52 周最低价为 6.57 美元，最高价为 22.93 美元。</p>
<p>89bio（纳斯达克股票代码：ETNB）于 5 月 15 日发布了最新的财报。公司报告季度每股亏损 0.54 美元，低于市场预期的 0.46 美元。去年同期，公司每股亏损为 0.54 美元。股票分析师预计，89bio 今年将实现每股亏损 2.42 美元。</p>
<h2>机构投资者对 89bio 的看法</h2>
<p>一些大型投资者最近增加或减少了对该股票的持股。纽约州公共退休基金在去年第四季度增持了 89bio 4.8% 的股份。纽约州公共退休基金现在持有公司股票 26,041 股，价值 291,000 美元，上季度增持了 1,190 股。德克萨斯州教师退休系统在去年第四季度增加了 89bio 股票 9.0% 的持股。德克萨斯州教师退休系统现在持有公司股票 15,791 股，价值 176,000 美元，上季度增持了 1,299 股。PNC 金融服务集团在去年第四季度增加了 89bio 股票 10.1% 的持股。PNC 金融服务集团现在持有公司股票 14,760 股，价值 165,000 美元，上季度增持了 1,360 股。美国 Ameritas 投资合作伙伴公司在第一季度增加了 89bio 股票 28.4% 的持股。美国 Ameritas 投资合作伙伴公司现在持有公司股票 7,886 股，价值 92,000 美元，上季度增持了 1,744 股。最后，Wetzel 投资顾问公司在第一季度增加了 89bio 股票 66.7% 的持股。Wetzel 投资顾问公司现在持有公司股票 5,000 股，价值 58,000 美元，上季度增持了 2,000 股。</p>
<h2>关于 89bio（获取免费报告）</h2>
<p>89bio 公司是一家临床阶段生物制药公司，专注于开发和商业化治疗肝脏和心脏代谢疾病的疗法。其主要产品候选药物是 pegozafermin，一种糖基 PEG 化的成纤维细胞生长因子 21 类似物，用于治疗非酒精性脂肪肝炎；以及用于治疗严重高甘油三酯血症。</p>
<h2>阅读更多</h2>
<ul>
<li>我们喜欢的五支股票胜过 89bio</li>
<li>零售股投资解析</li>
<li>Autodesk 的季度业绩可能推动其重返最近的高点</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Oracle 股票中正在酝酿的泡沫，而且只会越来越大</li>
<li>3 家值得购买的医疗保健股息股票</li>
<li>Danaos 受益于集装箱运输需求增加</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVROQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVROQg"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 发现 AI 巨头？（来自达尔文）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTI1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTI1"/></p>
<h2>您现在是否应该投资 1,000 美元在 89bio？</h2>
<p>在考虑 89bio 之前，您会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 89bio 不在名单上。</p>
<p>尽管 89bio 目前在分析师中有&#34;中等买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

ETNB

纳斯达克 OMX 交易所

<p>89Bio（纳斯达克股票代码：ETNB）收到了来自康泰菲茨杰的 “增持” 评级和 29.00 美元的目标股价。其他分析师也对 ETNB 发表了评论，其中有两位持有 “持有” 评级，五位给出了 “买入” 评级。该股目前交易价格为 9.84 美元，52 周最低价为 6.57 美元，最高价为 22.93 美元。其市值为 9.6806 亿美元，专注于开发治疗肝脏和心脏代谢疾病的疗法</p>

<p>89bio (NASDAQ:ETNB - Get Free Report)'s stock had its &#34;overweight&#34; rating reiterated by Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They currently have a $29.00 price target on the stock. Cantor Fitzgerald's price objective would indicate a potential upside of 194.72% from the company's previous close.</p>
<div class="lb-trans"><p>根据彭博社报道，Cantor Fitzgerald 在周三发布的一份报告中重申了对 89bio（纳斯达克股票代码：ETNB）的&#34;超重&#34;评级。他们目前将该股票的目标价定为 29.00 美元。Cantor Fitzgerald 的目标价表明，与公司前一交易日收盘价相比，潜在上涨幅度为 194.72%。</p>
</div><p>A number of other equities research analysts have also recently commented on ETNB. Royal Bank of Canada decreased their price target on 89bio from $15.00 to $14.00 and set a &#34;sector perform&#34; rating on the stock in a report on Friday, March 1st. Bank of America reissued a &#34;buy&#34; rating and set a $30.00 price target on shares of 89bio in a report on Monday, April 22nd. Oppenheimer reissued a &#34;market perform&#34; rating on shares of 89bio in a report on Tuesday, March 5th. HC Wainwright reissued a &#34;buy&#34; rating and set a $29.00 price target on shares of 89bio in a report on Tuesday. Finally, Evercore ISI decreased their price target on 89bio from $37.00 to $33.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.14.</p>
<div class="lb-trans"><p>一些其他股票研究分析师最近也对 ETNB 发表了评论。加拿大皇家银行将 89bio 的目标价从 15.00 美元降至 14.00 美元，并在 3 月 1 日的报告中给予该股票&#34;行业表现&#34;评级。美国银行在 4 月 22 日的报告中重申了&#34;买入&#34;评级，并将 89bio 的目标价设定为 30.00 美元。Oppenheimer 在 3 月 5 日的报告中重申了对 89bio 的&#34;市场表现&#34;评级。HC Wainwright 在周二的报告中重申了对 89bio 的&#34;买入&#34;评级，并将目标价设定为 29.00 美元。最后，Evercore ISI 在 5 月 15 日的报告中将 89bio 的目标价从 37.00 美元降至 33.00 美元，并给予该股票&#34;跑赢市场&#34;评级。两位投资分析师对该股票进行了持有评级，而五位则给予了买入评级。根据 MarketBeat.com 的数据，公司的共识评级为&#34;中等买入&#34;，平均目标价为 28.14 美元。</p>
</div><p><strong>View Our Latest Analysis on 89bio</strong></p>
<div class="lb-trans"><p><strong>查看我们对 89bio 的最新分析</strong></p>
</div><h2>89bio Stock Performance</h2>
<div class="lb-trans"><h2>89bio 股票表现</h2>
</div><p>NASDAQ ETNB traded up $1.16 on Wednesday, hitting $9.84. 355,360 shares of the company traded hands, compared to its average volume of 1,108,966. The company has a market capitalization of $968.06 million, a price-to-earnings ratio of -4.91 and a beta of 1.11. The company has a current ratio of 15.03, a quick ratio of 15.03 and a debt-to-equity ratio of 0.05. The business's 50 day moving average price is $8.98 and its 200-day moving average price is $10.13. 89bio has a 52-week low of $6.57 and a 52-week high of $22.93.</p>
<div class="lb-trans"><p>纳斯达克 ETNB 周三上涨 1.16 美元，报 9.84 美元。公司股票交易量为 355,360 股，相比平均交易量 1,108,966 股有所减少。公司市值为 9.6806 亿美元，市盈率为-4.91，β系数为 1.11。公司流动比率为 15.03，速动比率为 15.03，负债权益比为 0.05。公司的 50 天移动平均价格为 8.98 美元，200 天移动平均价格为 10.13 美元。89bio 的 52 周最低价为 6.57 美元，最高价为 22.93 美元。</p>
</div><p>89bio (NASDAQ:ETNB - Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08). During the same quarter in the prior year, the firm posted ($0.54) earnings per share. Equities analysts expect that 89bio will post -2.42 earnings per share for the current year.</p>
<div class="lb-trans"><p>89bio（纳斯达克股票代码：ETNB）于 5 月 15 日发布了最新的财报。公司报告季度每股亏损 0.54 美元，低于市场预期的 0.46 美元。去年同期，公司每股亏损为 0.54 美元。股票分析师预计，89bio 今年将实现每股亏损 2.42 美元。</p>
</div><h2>Institutional Investors Weigh In On 89bio</h2>
<div class="lb-trans"><h2>机构投资者对 89bio 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund increased its stake in 89bio by 4.8% during the fourth quarter. New York State Common Retirement Fund now owns 26,041 shares of the company's stock worth $291,000 after acquiring an additional 1,190 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of 89bio by 9.0% during the fourth quarter. Teacher Retirement System of Texas now owns 15,791 shares of the company's stock valued at $176,000 after buying an additional 1,299 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of 89bio by 10.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 14,760 shares of the company's stock valued at $165,000 after buying an additional 1,360 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of 89bio by 28.4% during the first quarter. Ameritas Investment Partners Inc. now owns 7,886 shares of the company's stock valued at $92,000 after buying an additional 1,744 shares during the period. Finally, Wetzel Investment Advisors Inc. boosted its position in shares of 89bio by 66.7% during the first quarter. Wetzel Investment Advisors Inc. now owns 5,000 shares of the company's stock valued at $58,000 after buying an additional 2,000 shares during the period.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了对该股票的持股。纽约州公共退休基金在去年第四季度增持了 89bio 4.8% 的股份。纽约州公共退休基金现在持有公司股票 26,041 股，价值 291,000 美元，上季度增持了 1,190 股。德克萨斯州教师退休系统在去年第四季度增加了 89bio 股票 9.0% 的持股。德克萨斯州教师退休系统现在持有公司股票 15,791 股，价值 176,000 美元，上季度增持了 1,299 股。PNC 金融服务集团在去年第四季度增加了 89bio 股票 10.1% 的持股。PNC 金融服务集团现在持有公司股票 14,760 股，价值 165,000 美元，上季度增持了 1,360 股。美国 Ameritas 投资合作伙伴公司在第一季度增加了 89bio 股票 28.4% 的持股。美国 Ameritas 投资合作伙伴公司现在持有公司股票 7,886 股，价值 92,000 美元，上季度增持了 1,744 股。最后，Wetzel 投资顾问公司在第一季度增加了 89bio 股票 66.7% 的持股。Wetzel 投资顾问公司现在持有公司股票 5,000 股，价值 58,000 美元，上季度增持了 2,000 股。</p>
</div><h2>About 89bio (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 89bio（获取免费报告）</h2>
</div><p>89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.</p>
<div class="lb-trans"><p>89bio 公司是一家临床阶段生物制药公司，专注于开发和商业化治疗肝脏和心脏代谢疾病的疗法。其主要产品候选药物是 pegozafermin，一种糖基 PEG 化的成纤维细胞生长因子 21 类似物，用于治疗非酒精性脂肪肝炎；以及用于治疗严重高甘油三酯血症。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than 89bio</li>
<li>Retail Stocks Investing, Explained</li>
<li>Autodesk's Quarterly Results Could Drive It Back to Recent Highs</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>A Bubble is Brewing in Oracle Stock, and it’s Only Getting Bigger</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Danaos Benefits from Increasing Demand in Container Shipping</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>我们喜欢的五支股票胜过 89bio</li>
<li>零售股投资解析</li>
<li>Autodesk 的季度业绩可能推动其重返最近的高点</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Oracle 股票中正在酝酿的泡沫，而且只会越来越大</li>
<li>3 家值得购买的医疗保健股息股票</li>
<li>Danaos 受益于集装箱运输需求增加</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVROQg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ETNB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Discover AI Giants? (From Darwin)(Ad)</p>
<div class="lb-trans"><p>→ 发现 AI 巨头？（来自达尔文）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTI1" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8125&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in 89bio right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元在 89bio？</h2>
</div><p>Before you consider 89bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 89bio 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 89bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 89bio 不在名单上。</p>
</div><p>While 89bio currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 89bio 目前在分析师中有&#34;中等买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

89Bio（纳斯达克：ETNB）获得 Cantor Fitzgerald 的增持评级